The first European interdisciplinary ewing sarcoma research summit.
The first European interdisciplinary ewing sarcoma research summit.
复制标题
DOI：
10.3389/fonc.2012.00054
复制
发表时间：
2012
影响因子：
4.7
通讯作者：
Ladenstein R
中科院分区：
文献类型：
--
作者：
Kovar H;Alonso J;Aman P;Aryee DN;Ban J;Burchill SA;Burdach S;De Alava E;Delattre O;Dirksen U;Fourtouna A;Fulda S;Helman LJ;Herrero-Martin D;Hogendoorn PC;Kontny U;Lawlor ER;Lessnick SL;Llombart-Bosch A;Metzler M;Moriggl R;Niedan S;Potratz J;Redini F;Richter GH;Riedmann LT;Rossig C;Schäfer BW;Schwentner R;Scotlandi K;Sorensen PH;Staege MS;Tirode F;Toretsky J;Ventura S;Eggert A;Ladenstein R
欧洲儿童和青少年癌症研究网络（ENCCA）为癌症儿童研究和护理的利益相关者提供了一个互动平台。ENCCA的目标之一是建立基于生物学的优先级机制，用于选择创新靶点、药物和预后标志物，以供临床试验验证。特别是对于肉瘤，迫切需要新的治疗方案，因为目前的化疗治疗方案已经达到了他们的极限。这对于转移性尤文肉瘤（ES）是最明显的，其中长期存活率仍然低于20%。尽管我们对胚胎干细胞生物学的理解取得了重大进展，但由于研究的碎片化和缺乏制度化的讨论论坛，有希望的实验室结果的临床翻译尚未发生。为了填补这一空白，ENCCA于2011年12月召集了30名欧洲专家科学家和5名北美意见领袖，交流思想，讨论ES研究的最新技术水平和最新结果，并为即将到来的欧洲EWING 2008和EWING 2012临床试验提出生物学研究和新的有前途的治疗方法。
The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.